Theraly Fibrosis Inc. Licenses Scarab Genomics’ Bacterial Production Technologies for its Pharmaceutical Program
Credit: Scarab Genomics
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Scarab Genomics LLC, a global biotechnology company focused on developing breakthrough technologies in biomanufacturing by applying its proprietary Clean Genome® E. coli expression and production systems for the manufacturing of proteins, single chain antibodies, plasmid DNA including retroviral, lentiviral, and shRNA vectors, and RNA and Theraly Fibrosis Inc., a biopharmaceutical company with a mission to develop innovative medicines for curing fibrotic diseases, announced that they have entered into a license agreement to allow Theraly Fibrosis to fully exploit Scarab Genomics’ technology for the production of a protein for its core therapeutic program.
“We are very pleased to support Theraly Fibrosis’ therapeutic program with our unique technology,” said Dr. Pascal Longchamp, Scarab Genomics’ Chief Corporate and Commercial Officer. “Using the Clean Genome® E. coli we have expressed hundreds of biological targets ranging from proteins to single chain antibodies to RNA and DNA. In the process, Scarab has generated custom strains and vectors to address the specific challenges for each biological class, and if needed, further refined the system for each target. The versatility of our production system offers solutions not only for large-scale production of commercial products through seamless scale-up of the manufacturing process but also rapid turnaround production for personalized cancer vaccines for instance. This license further demonstrates the potential of the Clean Genome® E. coli as the platform of choice for manufacturing biologics.”
“We firmly believe that the cutting-edge technology of Scarab Genomics has the potential to dramatically enhance the efficiency of development of biological products,” said Viktor Roschke, Theraly Fibrosis CEO. "This will allow us to significantly speed up the delivery of our revolutionary drugs to patients in need." Under the agreement, Theraly Fibrosis Inc. has the exclusive right to use Scarab Genomics’ technology throughout the development and commercialization of its therapeutic protein for an upfront fee, clinical milestones and commercial payments. Specific terms of the license agreement were not disclosed.
“We are very pleased to support Theraly Fibrosis’ therapeutic program with our unique technology,” said Dr. Pascal Longchamp, Scarab Genomics’ Chief Corporate and Commercial Officer. “Using the Clean Genome® E. coli we have expressed hundreds of biological targets ranging from proteins to single chain antibodies to RNA and DNA. In the process, Scarab has generated custom strains and vectors to address the specific challenges for each biological class, and if needed, further refined the system for each target. The versatility of our production system offers solutions not only for large-scale production of commercial products through seamless scale-up of the manufacturing process but also rapid turnaround production for personalized cancer vaccines for instance. This license further demonstrates the potential of the Clean Genome® E. coli as the platform of choice for manufacturing biologics.”
“We firmly believe that the cutting-edge technology of Scarab Genomics has the potential to dramatically enhance the efficiency of development of biological products,” said Viktor Roschke, Theraly Fibrosis CEO. "This will allow us to significantly speed up the delivery of our revolutionary drugs to patients in need." Under the agreement, Theraly Fibrosis Inc. has the exclusive right to use Scarab Genomics’ technology throughout the development and commercialization of its therapeutic protein for an upfront fee, clinical milestones and commercial payments. Specific terms of the license agreement were not disclosed.
